Krystal Biotech's Vyjuvek Achieves Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 14 2024
0mins
Should l Buy KRYS?
Source: SeekingAlpha
Krystal Biotech Inc. saw its stock rise by 4.56% as it reached a 20-day high, reflecting positive investor sentiment.
The company's recent approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, has led to impressive revenue of $389.1 million in 2023, marking a 34% year-over-year increase. This strong performance highlights the significant market potential in rare diseases, positioning Krystal Biotech favorably in the biotech sector.
As Krystal Biotech continues to innovate and expand its product offerings, the company is likely to attract further investor interest, especially given the growing demand for effective treatments in rare disease markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 274.210
Low
198.00
Averages
229.25
High
278.00
Current: 274.210
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
Vertex Pharmaceuticals Faces Competitive Threats
- Market Competition Risk: Vertex Pharmaceuticals faces significant threats as companies like Krystal Biotech develop new cystic fibrosis drugs, particularly KB407, which has the potential to treat all CF patients and could lead to Vertex losing market share for 95% of U.S. patients.
- Core Business Security: Despite the competitive landscape, Vertex's core franchise appears secure for the foreseeable future, primarily due to its monopoly in the cystic fibrosis drug market, with key products protected by patents until the late 2030s.
- Product Diversification Strategy: Vertex is actively pursuing diversification of its product lineup, having launched new drugs like Casgevy and Journavx over the past three years, and is expected to gain additional approvals in the coming years, enhancing its competitive edge.
- R&D Progress: Vertex recently reported strong phase 3 results for povetacicept, an investigational drug for IgA nephropathy, and plans to announce more phase 3 results by year-end, potentially leading to regulatory approvals for treatments targeting APOL1-mediated kidney disease, further solidifying its market position.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Innovative Drug Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa (DEB), marking it as the first approved treatment for this condition, showcasing the company's strength in drug innovation.
- Significant Sales Growth: In 2025, Krystal Biotech's revenue increased by 34% year-over-year to $389.1 million, and the company achieved profitability with earnings per share of $6.84 in 2024, indicating strong performance and pricing power in the DEB market.
- Huge Market Potential: The company targets approximately 1,200 DEB patients in the U.S. and around 1,300 in Japan and some European nations, with unmet market needs suggesting significant opportunities for further market share expansion through new product launches.
- Long-Term Uncertainty: Despite strong performance in the DEB sector, Krystal Biotech faces potential competition and clinical or regulatory risks, making its ability to sustain growth uncertain, thus investors should carefully assess its long-term investment value.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Strong Market Performance: Krystal Biotech's stock has surged over 230% since 2021, and despite having only one marketed product, its promising drug pipeline indicates significant growth potential, positioning it as a key player in the biotech sector.
- Innovative Therapy Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, the first gene therapy for Dystrophic Epidermolysis Bullosa (DEB), addressing a critical unmet need in the market and further solidifying the company's market position.
- Solid Financial Performance: In 2025, the company reported a 34% year-over-year revenue increase to $389.1 million, with earnings per share at $6.84, showcasing a rare achievement of profitability in the biotech space, which boosts investor confidence.
- Future Growth Potential: Krystal Biotech's pipeline includes candidates for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease, and if successful in launching new products, it could significantly enhance sales and profits, driving sustained growth over the next two decades.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
Vertex Pharmaceuticals Faces Competitive Threats
- Market Competition Risk: Vertex Pharmaceuticals faces significant threats as companies like Krystal Biotech develop new cystic fibrosis drugs, particularly KB407, which has the potential to treat all CF patients and could lead to Vertex losing market share for 95% of U.S. patients.
- Core Business Security: Despite the competitive landscape, Vertex's core franchise appears secure for the foreseeable future, primarily due to its monopoly in the cystic fibrosis drug market, with key products protected by patents until the late 2030s.
- Product Diversification Strategy: Vertex is actively pursuing diversification of its product lineup, having launched new drugs like Casgevy and Journavx over the past three years, and is expected to gain additional approvals in the coming years, enhancing its competitive edge.
- R&D Progress: Vertex recently reported strong phase 3 results for povetacicept, an investigational drug for IgA nephropathy, and plans to announce more phase 3 results by year-end, potentially leading to regulatory approvals for treatments targeting APOL1-mediated kidney disease, further solidifying its market position.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Innovative Drug Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa (DEB), marking it as the first approved treatment for this condition, showcasing the company's strength in drug innovation.
- Significant Sales Growth: In 2025, Krystal Biotech's revenue increased by 34% year-over-year to $389.1 million, and the company achieved profitability with earnings per share of $6.84 in 2024, indicating strong performance and pricing power in the DEB market.
- Huge Market Potential: The company targets approximately 1,200 DEB patients in the U.S. and around 1,300 in Japan and some European nations, with unmet market needs suggesting significant opportunities for further market share expansion through new product launches.
- Long-Term Uncertainty: Despite strong performance in the DEB sector, Krystal Biotech faces potential competition and clinical or regulatory risks, making its ability to sustain growth uncertain, thus investors should carefully assess its long-term investment value.
See More
Krystal Biotech Shares Surge Over 230% Since 2021
- Strong Market Performance: Krystal Biotech's stock has surged over 230% since 2021, and despite having only one marketed product, its promising drug pipeline indicates significant growth potential, positioning it as a key player in the biotech sector.
- Innovative Therapy Approval: In 2023, Krystal Biotech received FDA approval for Vyjuvek, the first gene therapy for Dystrophic Epidermolysis Bullosa (DEB), addressing a critical unmet need in the market and further solidifying the company's market position.
- Solid Financial Performance: In 2025, the company reported a 34% year-over-year revenue increase to $389.1 million, with earnings per share at $6.84, showcasing a rare achievement of profitability in the biotech space, which boosts investor confidence.
- Future Growth Potential: Krystal Biotech's pipeline includes candidates for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease, and if successful in launching new products, it could significantly enhance sales and profits, driving sustained growth over the next two decades.
See More
